10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Recombinant Human IGF-BP6

Catalog # PBG10175

Specification

Recombinant Human IGF-BP6 - Product Information

Recombinant Human IGF-BP6 - Additional Information

Description
IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant human IGF-BP6 has a calculated mass of 22.6 kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.

 *Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc.

BiologicalActivity
Determined by its ability to inhibit IGF-II induced proliferation of human MCF-7 cells. The expected ED₅₀ for this effect is 0.1 – 0.4 µg/ml.

Authenticity
Verified by N-terminal and Mass Spectrometry analyses (when applicable).

Endotoxin
Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg).

Protein Content
Verified by UV Spectroscopy and/or SDS-PAGE gel.

Storage
-20°C

Precautions
Recombinant Human IGF-BP6 is for research use only and not for use in diagnostic or therapeutic procedures.

Recombinant Human IGF-BP6 - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence

- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Recombinant Human IGF-BP6 - Images